In the US, Loracarbef (loracarbef systemic) is a member of the drug class second generation cephalosporins and is used to treat Bacterial Infection, Bladder Infection, Bronchitis, Impetigo, Kidney Infections, Otitis Media, Pneumonia, Sinusitis, Skin or Soft Tissue Infection, Tonsillitis/Pharyngitis and Upper Respiratory Tract Infection.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
3-Chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, (6R,7S)-7-[(R)-2-amino-2-phenylacetamido]
- Loracarbefum (Latin)
- Loracarbef (German)
- Loracarbef (French)
- Loracarbef (Spanish)
- Loracarbef (OS: BAN)
- LY 163892 (IS: Eli Lilly)
- Loracarbef (OS: USAN)
- Loracarbef (PH: USP 38)
Eli Lilly, Lithuania
|BAN||British Approved Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.